Trial reportEuropean journal of nuclear medicine and molecular imaging2022
A prospective randomized, double-blind study to evaluate the diagnostic efficacy of
Trial report in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04318561 (A Prospective, Randomized, Double-blinded Study to Evaluate the Safety, Biodistribution, Dosimetry and Lesion Detection Ability of Gallium-68 Labeled LM3 for the Diagnostic Imaging of Metastatic, Well-differentiated Neuroendocrine Tumors Using PET/CT), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized, Double-blinded Study to Evaluate the Safety, Biodistribution, Dosimetry and Lesion Detection Ability of Gallium-68 Labeled LM3 for the Diagnostic Imaging of Metastatic, Well-differentiated Neuroendocrine Tumors Using PET/CT
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Assessment of the diagnostic efficacy and clinical significance of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Evaluation of the safety, biodistribution, dosimetry of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Development of dual SSTRSC medicinal chemistry · 2026Article
- Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.Journal of neuroendocrinology · 2026Review
- Gallium-Containing Agents for Tumor Diagnosis and Therapy: Current Status and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies.Journal of clinical medicine · 2026Review
- Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025Review
- Molecular imaging of neuroendocrine tumors: Current applications and future trends.Diagnostic and interventional imaging · 2025Review
- Review
- Emerging innovations in theranostics for pancreatic neuroendocrine tumors.NPJ precision oncology · 2025Review
- Cytotoxicity Comparison ofMolecules (Basel, Switzerland) · 2025Article
- Synthesis and preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Research process of PET tracers for neuroendocrine tumors diagnosis.American journal of nuclear medicine and molecular imaging · 2025Review
- First-in-human study of an optimized, potential kit-type, SSTR antagonistTheranostics · 2025Article
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
- Enhanced Detection of Early Pulmonary Fibrosis Disease UsingMolecular pharmaceutics · 2024Article
- Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers.Journal of clinical medicine · 2024Review
- Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.European journal of nuclear medicine and molecular imaging · 2024Article
- SSTR antagonist [European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to evaluate the diagnostic efficacy of
methodsPatients were prospectively recruited and equally randomized into two arms: Arm A, patients would undergo a whole-body
resultsA total of 40 patients with well-differentiated NETs, 20 in each arm, were recruited in the study.
conclusionBoth
trial registrationClinicalTrials.gov identifier: NCT04318561.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.